111 (NASDAQ:YI – Get Free Report) and HeartSciences (NASDAQ:HSCS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current ratings for 111 and HeartSciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
HeartSciences has a consensus price target of $8.00, indicating a potential upside of 219.36%. Given HeartSciences’ stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than 111.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 111 | $1.80 billion | 0.02 | -$9.65 million | ($1.40) | -2.74 |
| HeartSciences | $8,669.00 | 920.34 | -$8.77 million | ($4.94) | -0.51 |
HeartSciences has lower revenue, but higher earnings than 111. 111 is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
111 has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Profitability
This table compares 111 and HeartSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 111 | -0.76% | N/A | -3.80% |
| HeartSciences | N/A | -333.50% | -140.18% |
Institutional & Insider Ownership
21.3% of 111 shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
HeartSciences beats 111 on 8 of the 14 factors compared between the two stocks.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
